Guangzhou Wondfo Biotech Co.,Ltd Stock price

Equities

300482

CNE100002102

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-02-22 pm EST 5-day change 1st Jan Change
26.07 CNY +1.36% Intraday chart for Guangzhou Wondfo Biotech Co.,Ltd -1.14% -13.59%
Sales 2023 * 2.72B 379M Sales 2024 * 3.45B 479M Capitalization 11.53B 1.6B
Net income 2023 * 468M 65.05M Net income 2024 * 653M 90.76M EV / Sales 2023 * 4.23 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 3.34 x
P/E ratio 2023 *
24.8 x
P/E ratio 2024 *
17.8 x
Employees 3,459
Yield 2023 *
0.96%
Yield 2024 *
1.15%
Free-Float 53.79%
More Fundamentals * Assessed data
Dynamic Chart
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback Plan announced on July 5, 2023. CI
Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback announced on July 5, 2023 has closed with 1,121,900 shares, representing 0.25% for CNY 30.1 million. CI
Guangzhou Wondfo Biotech Co.,Ltd announces an Equity Buyback for CNY 50 million worth of its shares. CI
Guangzhou Wondfo Biotech Co.,Ltd authorizes a Buyback Plan. CI
Beijing PolySeq Technology Co., Ltd. announced that it has received CNY 100 million in funding from Guangzhou Wondfo Biotech Co.,Ltd, Guangzhou Sanmei Investment Management Center (Limited Partnership), Shangshi Capital, IDG Capital Partners Co., Ltd., Tsinghua Innovation Ventures CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guangzhou Wondfo Biotech Co.,Ltd Approves the Cash Dividend for the Year 2022, Payable on 18 May 2023 CI
Announcement on Resolutions of the 2022 Annual General Meeting of Guangzhou Wondfo Biotech CI
Guangzhou Huiyin Tianyue Nominates Mr.Ge Xinhua as Supervisor CI
Guangzhou Wondfo Biotech Co.,Ltd Proposes Final Cash Dividend for the Year 2022 CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Beijing PolySeq Technology Co., Ltd. announced that it expects to receive CNY 40 million in funding from Guangzhou Wondfo Biotech Co.,Ltd, Guangzhou Sanmei Investment Management Center (Limited Partnership), Shangshi Capital, IDG Capital Partners Co., Ltd., Tsinghua Innovation Ventures CI
Investors bet on greed and fear as China loosens COVID grip RE
More news
1 day+1.36%
1 week-1.14%
Current month+8.17%
1 month-2.91%
3 months-12.98%
6 months+8.17%
Current year-13.59%
More quotes
1 week
25.43
Extreme 25.43
27.00
1 month
20.52
Extreme 20.52
28.15
Current year
20.52
Extreme 20.52
31.00
1 year
20.52
Extreme 20.52
34.10
3 years
20.52
Extreme 20.52
81.54
5 years
20.52
Extreme 20.52
85.38
10 years
4.47
Extreme 4.4744
85.38
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 09-12-31
Founder 61 91-12-31
Founder 61 91-12-31
Members of the board TitleAgeSince
Founder 61 91-12-31
Chairman 62 12-04-10
Founder 61 91-12-31
More insiders
Date Price Change Volume
24-02-23 26.07 +1.36% 3,981,930
24-02-22 25.72 -0.89% 4,383,030
24-02-21 25.95 -1.22% 3,300,461
24-02-20 26.27 +1.04% 2,949,899

End-of-day quote Shenzhen S.E., February 22, 2024

More quotes
GUANGZHOU WONDFO BIOTECH CO., LTD. is a China-based company principally engaged in research, manufacture and sales of point-of-care testing (POCT) reagents, POCT instrument and related products. According to the testing result, the Company' products can be divided into qualitative testing products and quantitative testing products. According to the usage, the Company' products include pregnancy testing series, infectious diseases testing series, drugs (drug abuse) testing series and chronic disease testing series. The Company's products are used in POCT, clinical test, field test and personal health management, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
26.07 CNY
Average target price
36.36 CNY
Spread / Average Target
+39.48%
Consensus
  1. Stock
  2. Equities
  3. Stock Guangzhou Wondfo Biotech Co.,Ltd - Shenzhen S.E.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer